{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-049994","form_type":"8-K","ticker":"KAPA","cik":"0001962011","company_name":"Kairos Pharma, LTD.","filed_at":"2024-12-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.454364+00:00","generated_at":"2026-05-29T03:45:03.934567+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Kairos Pharma appoints Rahul Singhvi as director, replacing Rosemary Mazanet","bullets":["Dr. Rosemary Mazanet resigned from board effective upon appointment of new independent director; not due to disagreement.","Dr. Rahul Singhvi appointed director effective Dec 10, 2024; will serve on audit committee, chair compensation and nominating/corporate governance committees.","Singhvi is cofounder of Resilience, former CEO of Novavax (NVAX), former COO of Takeda's Vaccine business.","Singhvi receives $50K annual cash fee and $50K in RSUs vesting over three years under 2023 Equity Incentive Plan."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-049994","json":"https://secwatch.observer/filing/0001493152-24-049994.json","markdown":"https://secwatch.observer/filing/0001493152-24-049994.md","text":"https://secwatch.observer/filing/0001493152-24-049994.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1962011/000149315224049994/0001493152-24-049994-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1962011/000149315224049994/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T03:45:03.934567+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}